Skip to main content
    K

    Kura Oncology Inc (KURA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.09
    -0.68 (-8.75%)

    Market Cap: $713.90M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Kura Oncology Inc (KURA) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Kura Oncology (KURA) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Kura Oncology reported EPS of -$0.78, above the -$0.83 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    55%(22/40)
    Avg Surprise
    -14.04%
    Streak
    3 Q

    Upcoming Estimates

    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.86
    Range-$1.07 - -$0.72
    17 analysts
    Revenue Consensus
    $31.68M
    Range$21.53M - $86.00M
    17 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.69
    Range-$0.79 - -$0.60
    3 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.72+4.0%
    60d ago-$0.67-3.3%
    30d ago-$0.68-1.0%
    7d ago-$0.68-1.0%
    Current-$0.69
    Revenue Consensus
    $41.77M
    Range$33.30M - $47.00M
    4 analysts

    Next Report

    KURA has an expected report date of Mar 3, 2027.

    KURA Earnings Call

    The latest KURA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, KURA beat 22, missed 12 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $22.84M, up 10.1% from $20.75M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.78-$0.83-$0.99 - -$0.70+6.02%BeatN/A11N/ANov 10, 2026$22.84M
    Jun 30, 2026-$0.77-$0.89-$1.02 - -$0.72+13.48%BeatN/A91 up, 0 downAug 12, 2026$20.87M
    Mar 31, 2026-$0.83-$0.90-$1.06 - $0.47+8.35%BeatN/A90 up, 3 downMay 12, 2026$18.27M
    Dec 31, 2025-$0.92-$0.49-$0.99 - $0.11-87.76%MissN/A91 up, 4 downMar 5, 2026$17.34M
    Sep 30, 2025-$0.85-$0.68-$0.98 - $0.49-25.00%MissN/A91 up, 6 downNov 4, 2025$20.75M
    Jun 30, 2025-$0.75$0.15-$0.86 - $0.18-600.00%MissN/A95 up, 2 downAug 7, 2025$15.29M
    Mar 31, 2025-$0.66-$0.60-$0.84 - -$0.04-10.00%MissN/A81 up, 5 downMay 1, 2025$14.11M
    Dec 31, 2024-$0.22-$0.64-$0.75 - -$0.39+65.49%BeatN/A104 up, 4 downFeb 26, 2025$53.88M
    Sep 30, 2024-$0.63-$0.61-$0.67 - -$0.57-3.28%MissN/A140 up, 0 downNov 7, 2024N/A
    Jun 30, 2024-$0.59-$0.62-$0.69 - -$0.57+4.84%BeatN/A120 up, 0 downAug 8, 2024N/A
    Mar 31, 2024-$0.59-$0.54-$0.68 - -$0.44-9.26%MissN/A110 up, 0 downMay 2, 2024N/A
    Dec 31, 2023-$0.55-$0.55-$0.68 - -$0.490.00%In lineN/A142 up, 0 downFeb 27, 2024$1.27M
    Sep 30, 2023-$0.50-$0.55-$0.68 - -$0.50+9.09%BeatN/A130 up, 0 downNov 2, 2023N/A
    Jun 30, 2023-$0.53-$0.56-$0.69 - -$0.51+5.36%BeatN/A120 up, 0 downAug 3, 2023N/A
    Mar 31, 2023-$0.50-$0.54-$0.65 - -$0.49+7.41%BeatN/A90 up, 0 downMay 10, 2023N/A
    Dec 31, 2022-$0.49-$0.57-$0.65 - -$0.53+14.04%BeatN/A100 up, 0 downFeb 23, 2023N/A
    Sep 30, 2022-$0.53-$0.56-$0.66 - -$0.53+5.36%BeatN/A90 up, 0 downNov 3, 2022N/A
    Jun 30, 2022-$0.52-$0.52-$0.61 - -$0.490.00%In lineN/A90 up, 0 downAug 3, 2022N/A
    Mar 31, 2022-$0.49-$0.52-$0.53 - -$0.50+5.77%BeatN/A70 up, 0 downMay 4, 2022N/A
    Dec 31, 2021-$0.49-$0.53-$0.62 - -$0.48+7.55%BeatN/A81 up, 0 downFeb 24, 2022N/A
    Sep 30, 2021-$0.50-$0.54-$0.64 - -$0.51+7.41%BeatN/A70 up, 0 downNov 4, 2021N/A
    Jun 30, 2021-$0.51-$0.50-$0.61 - -$0.44-2.00%MissN/A7N/AAug 5, 2021N/A
    Mar 31, 2021-$0.46-$0.42-$0.46 - -$0.39-9.52%MissN/A6N/AMay 6, 2021N/A
    Dec 31, 2020-$0.45-$0.45-$0.61 - -$0.400.00%In lineN/A10N/AFeb 24, 2021N/A
    Sep 30, 2020-$0.42-$0.40-$0.50 - -$0.30-5.00%MissN/A8N/ANov 5, 2020N/A
    Jun 30, 2020-$0.40-$0.43-$0.46 - -$0.32+6.98%BeatN/A9N/AAug 6, 2020N/A
    Mar 31, 2020-$0.42-$0.42-$0.45 - -$0.330.00%In lineN/A7N/AMay 4, 2020N/A
    Dec 31, 2019-$0.39-$0.41-$0.49 - -$0.38+4.88%BeatN/A8N/AFeb 25, 2020N/A
    Sep 30, 2019-$0.36-$0.39-$0.44 - -$0.35+7.69%BeatN/A9N/ANov 5, 2019N/A
    Jun 30, 2019-$0.38-$0.41-$0.46 - -$0.36+7.32%BeatN/A8N/AAug 1, 2019N/A
    Mar 31, 2019-$0.37-$0.44-$0.46 - -$0.42+15.91%BeatN/A7N/AMay 7, 2019N/A
    Dec 31, 2018-$0.42-$0.42-$0.46 - -$0.370.00%In lineN/A8N/AMar 5, 2019$2.44M
    Sep 30, 2018-$0.40-$0.43-$0.47 - -$0.40+6.98%BeatN/A7N/ANov 5, 2018N/A
    Jun 30, 2018-$0.45-$0.43-$0.51 - -$0.34-4.65%MissN/A5N/AAug 6, 2018N/A
    Mar 31, 2018-$0.46-$0.35-$0.38 - -$0.30-31.43%MissN/A6N/AMay 8, 2018N/A
    Dec 31, 2017-$0.37-$0.36-$0.41 - -$0.32-2.78%MissN/A6N/AMar 12, 2018N/A
    Sep 30, 2017-$0.38-$0.38-$0.49 - -$0.290.00%In lineN/A5N/ANov 7, 2017N/A
    Jun 30, 2017-$0.40-$0.43-$0.44 - -$0.41+6.98%BeatN/A4N/AAug 7, 2017N/A
    Mar 31, 2017-$0.39-$0.42-$0.50 - -$0.40+7.14%BeatN/A4N/AMay 15, 2017N/A
    Dec 31, 2016-$0.38-$0.40N/A+5.00%BeatN/AN/AN/AMar 14, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.18, after -$2.03 the year before. It was -$1.47 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.18N/A
    Dec 31, 2024-$2.03N/A
    Dec 31, 2023-$2.08N/A
    Dec 31, 2022-$2.03N/A
    Dec 31, 2021-$1.96N/A
    Dec 31, 2020-$1.69N/A
    Dec 31, 2019-$1.50N/A
    Dec 31, 2018-$1.73N/A
    Dec 31, 2017-$1.54N/A
    Dec 31, 2016-$1.47N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,900 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,90716
    2026Q2Jun 30, 20266,02217
    2026Q1Mar 31, 20265,40217
    2025Q4Dec 31, 20255,76216
    2025Q3Sep 30, 20255,42813
    2025Q2Jun 30, 20257,32116
    2025Q1Mar 31, 20257,02217
    2024Q4Dec 31, 20248,99117

    2026Q3 Earnings Call

    Opening remarks

    Greg Mann SVP of Investor Relations and Corporate Affairs Thank you, Ronnie. Good afternoon, everyone. Joining me today are Dr. Troy Edward Wilson, President and Chief Executive Officer; Brian T. Powl, Chief Commercial Officer; Dr. Mollie Leoni, Chief Medical Officer; and Jennifer Fulk, Chief Financial Officer. Today's discussion includes forward-looking statements based on our current expectations and management's judgment as of today. Actual results could differ materially because of risks and uncertainties, including those described in our SEC filings. Please refer to these filings, which are available through the SEC and on our website, for information concerning risk factors that could affect the company. With that, I will turn the call over to Troy.

    Troy Edward Wilson President and Chief Executive Officer Thank you, Greg. Good afternoon, everyone. I am happy to report we delivered another quarter of strong growth and sustained commercial leadership. COMZIFTI net product revenue reached $13.9 million, up 53% sequentially, and new patient starts increased 30%. We maintained majority share of menin inhibitor new patient starts, reflecting continued physician preference for COMZIFTI. Our priority is to grow our leadership in this setting while building the clinical evidence to support expansion into earlier treatment settings and combinations. We are heading into ASH with an unprecedented ziftomenib presence, including four oral presentations and our first clinical data on ziftomenib combined with FLT3 inhibitors in both newly diagnosed and relapsed or refractory AML. Roughly half of patients with NPM1-mutated AML have a concurrent FLT3 mutation, and that prevalence makes FLT3 inhibitor combinations a critical part of our strategy to establish ziftomenib as a foundational AML therapy. These studies are among eight ziftomenib abstracts at ASH, and Mollie will discuss how these studies address the opportunity and inform our next development decisions. Turning to our FTI program, we are very excited to announce we have aligned with the FDA on a single-arm monotherapy registrational study with darlafarnib in HRAS-mutant salivary gland cancer. This puts our second potential precision oncology product on a focused path toward registration. This approach may deliver a new class of treatment in a molecularly defined patient population with substantial unmet need. Importantly, it could also provide a strong clinical, regulatory, and commercial foundation while we pursue larger indications in combination and through supplemental applications. We enter this next phase for Kura from a position of financial strength. Our strategic financing agreement with OrbiMed gives us flexibility to deliver key milestones for ziftomenib and darlafarnib. I am pleased to welcome Jennifer to her first call as our Chief Financial Officer. She will discuss the financing, funding outlook, and our capital allocation priorities. Finally, we established Caspian Therapeutics to advance menin inhibitors for diabetes and other chronic metabolic diseases. Kura contributed KO-7.25 thousand and related intellectual property and know-how.

    Frequently Asked Questions About KURA

    When is Kura Oncology's next earnings date?

    Kura Oncology's next earnings report is expected for Mar 3, 2027.

    Did KURA beat earnings estimates last quarter?

    Yes. Kura Oncology reported EPS of -$0.78 for the quarter ended Sep 30, 2026, above the -$0.83 estimate, a 6.02% surprise.

    What EPS do analysts expect from KURA next quarter?

    The consensus EPS estimate for Kura Oncology for the quarter ending Dec 31, 2026 is -$0.86 from 17 analysts, with estimates from -$1.07 to -$0.72.

    How often does KURA beat earnings estimates?

    Kura Oncology beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -78.68%.